VHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VHI is not a good buy right now for an impatient investor. The technical setup is neutral (no strong momentum signal, price near pivot), and fundamentals recently deteriorated sharply (losses and margin compression). With no Intellectia buy signals and earnings approaching (2026-02-05), the near-term risk/reward isn’t compelling for an immediate entry.
Price/Trend: VHI closed at 14.47 (+1.94%) and is sitting just above the pivot (14.366), which suggests a neutral-to-slightly-bullish near-term posture but not a breakout. Momentum: MACD histogram is slightly positive (0.00349) but positively contracting, implying bullish momentum is weak and fading rather than accelerating. RSI(6) at 52.7 is neutral—no oversold bounce signal and no overbought strength. Moving Averages: Converging moving averages point to consolidation/range behavior rather than a trending move. Levels: Key support is S1 13.487 (then S2 12.945). Resistance is R1 15.245 (then R2 15.787). For an impatient buyer, upside is capped unless it clears ~15.25 decisively; downside risk reopens if it loses ~13.49. Pattern-based forward view: Similar-pattern stats imply mixed outcomes (next day: 40% chance of -0.76%; next week: +3.41%; next month: +0.08%), which reinforces a “range/uncertain” setup.
Intellectia Proprietary Trading Signals
Earnings event upcoming (2026-02-05 after hours): could catalyze a re-rating if results show stabilization or margin recovery.
Price is holding above pivot with nearby resistance at 15.245—any breakout above that level could attract short-term momentum buyers.
No notable hedge-fund or insider selling pressure reported recently (both neutral).
was weak: revenue down YoY and profitability deteriorated sharply (losses, EPS negative).
Latest quarter: 2025/Q3. Revenue was $503.5M (-5.64% YoY). Net income declined to -$22.2M (down -138.61% YoY), and EPS was -0.78 (down -138.61% YoY). Gross margin fell to 12.04% (-44.77% YoY). Overall trend: weakening growth and significant margin compression, which is unfavorable for an immediate buy thesis.
No analyst rating or price target change data was provided, so a clear Wall Street consensus (pros/cons) cannot be confirmed from the dataset. Based on the available fundamentals alone, the ‘pro’ case would rely on a cyclical rebound or margin recovery; the ‘con’ case is current losses and sharply lower margins, which typically suppress investor appetite until improvement is visible.
